Influenza B virus replication for vaccine development
US11197925B2 · kind B2 · utility
13Cited by
65References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 17, 2017 |
| Grant date | Dec 14, 2021 |
| Priority date | — |
| Expiry date | Jun 15, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16251
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a composition useful to prepare high titer influenza B viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza B virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.